Catheter Precision Inc.
$31.3K 40 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ProgenaCare Global, LLC
ProgenaCare Global, LLC reported $31,321.71 across General Payments, Research, and Ownership to 385 physicians and teaching hospitals across 385 transactions.
- $31.3K Below-median payer
- All-tracks total
- 385 Above-median volume
- Transactions
- 385 Above-median reach
- Recipients
- −$136.7K
- General Payments vs PY2023
ProgenaCare Global, LLC reported $31,321.71 across all CMS Open Payments tracks (General + Research + Ownership) to 385 physicians and teaching hospitals in Program Year 2024 - ranking #1460 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $31,321.71, averaging $81.36 per recipient.
ProgenaCare Global, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
10/100
Transaction volume
F
13/100
Physician reach
F
13/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer progenacare-global-llc ProgenaCare Global, LLC
$31.3K · #1460/1,925 · 0.0% industry · PY2024
- TOT $31.3K
- RANK #1460
- SHARE 0.0%
- TXN 385
- RCP 385
- CAT 3
- GEN $31.3K
- ΔGEN −$136.7K
- TOP1 52.7%
- PY 2024
Volume peers
Nearest volume peer: Catheter Precision Inc. ($31.3K)
ProgenaCare Global, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ProgenaCare Global, LLC's CMS-reported General Payments decreased by $136.7K (−81.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: PROGENACARE GLOBAL, LLCPY2024: ProgenaCare Global, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $168,011.06
- PY2024
- $31,321.71
What the Data Shows for ProgenaCare Global, LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For ProgenaCare Global, LLC that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $12.9K across 11 transactions, 41.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads ProgenaCare Global, LLC's 3-category general-payment breakdown at $12.9K, 41.3% of the reported total.
How ProgenaCare Global, LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $12.9K | 11 | 41.3% |
| Food and Beverage | $12.3K | 361 | 39.1% |
| Travel and Lodging | $6.1K | 13 | 19.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $21,598.97 (69.0%) of $31,321.71 in this company's General Payments records across 186 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ProgenaCare Global, LLC
The five named recipients with the highest reported General Payments from this company
- 1
John Stephen Starinski
$16,520.77 across 30 reported transactions
- 2
Gregory Sheremeta
$3,742.74 across 20 reported transactions
- 3
Daniel Ea Thomas
$485.45 across 1 reported transactions
- 4
Shawn Leslie Reiser
$429.56 across 16 reported transactions
- 5
Sarah Christine Hewitt
$420.45 across 14 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
ProgenaCare Global, LLC ranks #1460 of 1,925 by total payments (bottom 24% by spend) but is notably more concentrated than that alone would suggest -- #576 of 1,838 by HHI (top 31% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Biogennix, LLC : $352.9K total payments, HHI 2990
- L&K Spine Inc : $111.3K total payments, HHI 2966
- Sirius Medical Systems : $139.4K total payments, HHI 2964
- Momentis Surgical Inc. : $54.4K total payments, HHI 2960
- Beckman Coulter, Inc. : $4.6M total payments, HHI 2954
- Circassia Inc. : $3.7K total payments, HHI 2949
- ProgenaCare Global, LLC (this company) : $31.3K total payments, HHI 2943
- Olea Medical : $161.8K total payments, HHI 2931
- GenMark Diagnostics, Inc. : $18.1K total payments, HHI 2927
- Evologics LLC : $222.2K total payments, HHI 2920
- Renalytix AI, Inc. : $131.1K total payments, HHI 2909
- ImpediMed, Inc. : $128.1K total payments, HHI 2895
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ProgenaCare Global, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ProgenaCare Global, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ProgenaCare Global, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Vitrolife Inc.
$31.3K 38 recipients
Compare payment profiles
Atlas Spine, Inc.
$31.3K 17 recipients
Compare payment profiles
Prexion, Inc.
$31.5K 23 recipients
Compare payment profiles
Lupin Inc.
$31.5K 12 recipients
Compare payment profiles
Optos plc
$31.7K 31 recipients
Compare payment profiles
Put this to use
ProgenaCare Global, LLC ranks #1460 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just ProgenaCare Global, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.